Clinicopathological features and prognosis of pseudomyxoma peritonei

HUAN WANG1*, XUEJUN WANG2*, YANFANG JU1, JINLIANG WANG1, XIN ZHANG1, YAO CHENG1, JING SUN1 and YI HU1

1Department of Oncology, The General Hospital of PLA, Beijing 100853; 2Department of Neurology, Qinghai Women Children's Hospital, Xining, Qinghai 810000, P.R. China

Received June 6, 2013; Accepted September 27, 2013

DOI: 10.3892/etm.2013.1408

Abstract. The aim of this study was to evaluate the effects of treatment and the factors influencing the postoperative recurrence and survival time for pseudomyxoma peritonei (PMP). A total of 39 patients with PMP who received treatment were analyzed in The General Hospital of PLA (Beijing, China) between 2002 and 2011. The patients received cytoreductive surgery (CRS) and 25 cases of PMP recurred. Seven patients received postoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). The median follow-up was 40 months. There were eight mortalities in this period. The 5- and 10-year survival rates were 89.0 and 35.0%, respectively. The medians of overall survival (OS) and recurrence time were 37 and 4 months, respectively. Multivariate analyses revealed that pathological subtype was able to influence the recurrence (P=0.042) and OS (P=0.033) times, as an independent prognostic factor. HIPEC was significantly associated with postoperative recurrence time (P=0.017). Patients with disseminated peritoneal adenomucinosis had a more favorable prognosis. CRS combined with HIPEC was able to extend the postoperative recurrence time for patients with PMP.

Introduction

Pseudomyxoma peritonei (PMP) is a rare disease with an incidence of ~2/10,000 (1). The majority of PMP cases are reported to originate from the ovaries and appendix. Females present more frequently with PMP and the male to female ratio is 1:3.4 (2). The patient usually presents with abdominal pain, bloating, abdominal mass, progressive increase of abdominal circumference, weight loss and fatigue; abdominal percussion dullness and signs of ascites are not obvious. Ascites is not easily removed from the mucinous liquid. This disease shows no marked specificity and misdiagnosis is easy. The course of the disease is long and relapse is common. The present study collected clinical data in The General Hospital of PLA (Beijing, China) between 2002 and 2011. The preoperative evaluation included thoracic and abdominal computed tomography (CT) scans or ultrasounds, as well as complete blood tests. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) have been the common treatments for PMP since the 1980s. A 5-year survival rate of 86% was reported in a study by Sugarbaker (3). The purpose of the present study was to evaluate the effects of treatment and the prognostic factors influencing the recurrence and overall survival (OS) times for PMP.

Materials and methods

Patients. A total of 39 patients were admitted to The General Hospital of PLA between 2002 and 2011. Retrospective analysis of the clinical data of 39 cases of PMP included age, gender, cardinal symptom, image analysis, treatment mode, pathological diagnosis, tumor markers (carcinoembryonic antigen, CEA; alpha-fetoprotein, AFP; cancer antigen 125, CA125) and postoperative adjuvant therapy. The patients met the clinical and pathological diagnostic criteria. The clinicopathological features of the 39 patients with PMP are shown in Table I. Peritoneal lesions were classified into three groups, consisting of disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA) and peritoneal mucinous carcinomatosis with intermediate or discordant features (PMCA-I/D). The common clinical symptoms and signs were abdominal bulge, abdominal distension, abdominal pain and massive ascites. Four patients were admitted for an abdominal mass. The patients underwent tumor marker measurements. Abdominal ultrasound and CT scans revealed the following: ascites; inward gathering of the intestinal canal; thickening of the peritoneum; widely distributed fluid sonoluent area in the peritoneal cavity, the surrounding of the liver and stomach and the interspaces of

Correspondence to: Dr Yi Hu, Department of Oncology, The General Hospital of PLA, 28 Fuxing Road, Haidian, Beijing 100853, P.R. China
E-mail: huyidoc@126.com

*Contributed equally

Key words: pseudomyxoma peritonei, cytoreductive surgery, hyperthermic intraperitoneal chemoperfusion, prognosis
the intestines; and thickening and calcification of the peritoneum with widespread and multiple small nodular foci. The informed consent was obtained from the patients or patient's family.

### Table I. Clinicopathological features of 39 cases of pseudomyxoma peritonei.

| Number | Gender | Age (years) | Pathology type | Tumor marker | Treatment | Recurrence time (months) | Survival time (months) |
|--------|--------|-------------|----------------|--------------|-----------|--------------------------|------------------------|
| 1      | M      | 61          | DPAM           | H H H H H    | HIPEC     | 0                        | 3+                     |
| 2      | F      | 69          | DPAM           | H H H H -    | IC        | 32                       | 37+                    |
| 3      | F      | 69          | DPAM           | H - H H H    | CS        | 53                       | 58+                    |
| 4      | M      | 61          | DPAM           | H H H H H    | PIC       | 0                        | 7+                     |
| 5      | M      | 58          | DPAM           | - - - - -    | CS        | 0                        | 8+                     |
| 6      | M      | 50          | DPAM           | H H H H H    | HIPEC     | 1                        | 16+                    |
| 7      | F      | 68          | DPAM           | - - - - -    | CS        | 0                        | 8+                     |
| 8      | M      | 65          | DPAM           | - - - - -    | HIPEC     | 27                       | 37                     |
| 9      | F      | 48          | DPAM           | - H H H -    | CS        | 0                        | 10+                    |
| 10     | F      | 65          | DPAM           | - - - - -    | CS        | 0                        | 11+                    |
| 11     | F      | 70          | PMCA           | - - - - -    | CS        | 1                        | 3+                     |
| 12     | F      | 74          | PMCA-I/D       | H H - H H    | CS        | 0                        | 2+                     |
| 13     | F      | 43          | DPAM           | - H H H H    | CS        | 0                        | 2+                     |
| 14     | F      | 67          | DPAM           | - - - - -    | CS        | 55                       | 18+                    |
| 15     | F      | 59          | DPAM           | - H H H H    | CS        | 32                       | 50+                    |
| 16     | M      | 62          | DPAM           | - - - - -    | CS        | 48                       | 13+                    |
| 17     | F      | 56          | DPAM           | H H H - -    | CS        | 24                       | 117                    |
| 18     | F      | 45          | DPAM           | H H - - -    | HIPEC     | 0                        | 30+                    |
| 19     | M      | 67          | DPAM           | H H H H -    | HIPEC     | 15                       | 32+                    |
| 20     | F      | 62          | DPAM           | H - - - -    | HIPEC     | 0                        | 31+                    |
| 21     | F      | 48          | PMCA-I/D       | H - H H H    | IC        | 27                       | 73+                    |
| 22     | F      | 70          | DPAM           | - - - - -    | CS        | 6                        | 25+                    |
| 23     | F      | 40          | DPAM           | H - - - H    | HIPEC     | 0                        | 25+                    |
| 24     | F      | 74          | DPAM           | - - - - -    | PIC       | 4                        | 27                     |
| 25     | M      | 45          | PMCA           | H H H H H    | IC        | 4                        | 55+                    |
| 26     | F      | 41          | DPAM           | - - - - -    | CS        | 12                       | 58+                    |
| 27     | F      | 76          | DPAM           | - - - - -    | CS        | 1                        | 144                    |
| 28     | F      | 34          | DPAM           | - - - - -    | CS        | 10                       | 58+                    |
| 29     | F      | 43          | DPAM           | - - H H H    | PIC       | 0                        | 60+                    |
| 30     | M      | 60          | DPAM           | - - - - -    | PIC       | 0                        | 50+                    |
| 31     | F      | 57          | DPAM           | - - - - -    | CS        | 21                       | 91+                    |
| 32     | M      | 43          | DPAM           | - - - - -    | CS        | 6                        | 105                    |
| 33     | M      | 47          | DPAM           | - - - - -    | PIC       | 65                       | 73+                    |
| 34     | F      | 80          | DPAM           | - - - - -    | CS        | 36                       | 75                     |
| 35     | M      | 67          | PMCA           | - - - - -    | CS        | 4                        | 90+                    |
| 36     | F      | 75          | DPAM           | - H - - -    | CS        | 0                        | 92                     |
| 37     | M      | 42          | DPAM           | H - H H H    | PIC       | 24                       | 93+                    |
| 38     | M      | 26          | DPAM           | - - - - -    | CS        | 12                       | 118+                   |
| 39     | M      | 70          | DPAM           | H - - - -    | PIC       | 235                      | 362                    |

M, male; F, female; IC, intravenous chemotherapy; CS, cytoreductive surgery; PIC, perioperative intraperitoneal chemotherapy; HIPEC, hyperthermic intraperitoneal chemoperfusion; H, high; DPAM, disseminated peritoneal adenomucinosis; PMCA-I/D, peritoneal mucinous carcinomatosis with intermediate or discordant features; PMCA, peritoneal mucinous carcinomatosis; CEA, carcinoembryonic antigen; AFP, alpha-fetoprotein; CA125, cancer antigen 125; +, more than.

**Treatment.** Surgical resection in combination with perioperative intraperitoneal chemotherapy (PIC) and HIPEC was the major treatment approach for PMP. Intraoperative chemotherapy medication included fluorouracil (5-FU), mitomycin and cispl-
atin, while HIPEC comprised 5-FU, cisplatin and heating to 43°C for 60 min. A total of 39 patients with PMP were treated with CRS. HIPEC was performed in seven patients (18%) at a temperature of 43°C, with cisplatin plus 5-FU. Twenty-two patients received PIC with cisplatin plus 5-FU.

Statistical analysis. OS and recurrence times were calculated from surgery to the time of mortality or post-surgical disease recurrence. Survival estimates were calculated using the Kaplan-Meier method. The log-rank test was used to assess the significance of the survival distribution. On the basis of univariate analysis, significant variables were included in a Cox proportional hazard model for multivariate analysis. All analyses were performed using SPSS 13.0 statistical software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Clinicopathological features. Among the 39 patients, 15 were male (38%) and 24 were female (62%). The median age was 61 years (range 26-80 years). Thirty-four patients were diagnosed with DPAM (67%), three with PMCA (8%) and two with PMCA-I/D (5%). The baseline marker levels were elevated in 20 patients prior to the surgery (51%), and 15 patients with an elevated marker level demonstrated recurrence following surgery (52%). All patients received surgery and 25 cases recurred. Thirteen patients underwent further surgery. Seven patients received HIPEC following surgery and three cases recurred. The evaluation methods included physical examination, CT scan and blood test.

Prognosis. With a mean follow-up of 40 months, the overall 5- and 10-year survival rates were 89 and 35%, respectively. The median OS and recurrence times were 37 and 4 months, respectively. The recurrence-free survival rates were 56 and 23% at 1 and 3 years, respectively. Table II shows a univariate model of the association between clinicopathological factors and survival. The log-rank test revealed that pathological type exerted an impact on recurrence time (P=0.047; Fig. 1) and OS (P=0.048; Fig. 2). The log-rank test also revealed preoperative

Table II. Univariate analysis of clinicopathological factors for survival.

| Variable                        | Total (n) | Recurrence (n) | Recurrence-free survival | Overall survival |
|---------------------------------|-----------|----------------|--------------------------|------------------|
| Gender                          |           |                |                          |                  |
| Male                            | 15        | 11             | 0.656                    | 0.325            |
| Female                          | 24        | 14             |                          |                  |
| Age                             |           |                |                          |                  |
| ≤61                             | 21        | 12             | 0.268                    | 0.155            |
| >61                             | 18        | 13             |                          |                  |
| Pathological type               |           |                |                          |                  |
| DPAM                            | 34        | 20             | 0.047                    | 0.048            |
| PMCA/PMCA-I/D                   | 5         | 3              |                          |                  |
| Tumor marker (preoperative)     |           |                |                          |                  |
| Elevated                        | 20        | 15             | 0.572                    | 0.027            |
| Normal                          | 19        | 10             |                          |                  |
| Type of intraperitoneal chemotherapy |        |                |                          |                  |
| PIC                             | 32        | 21             | 0.287                    | 0.296            |
| HIPEC                           | 7         | 3              |                          |                  |

DPAM, disseminated peritoneal adenomucinosis; PMCA-I/D, peritoneal mucinous carcinomatosis with intermediate or discordant features; PMCA, peritoneal mucinous carcinomatosis; PIC, perioperative intraperitoneal chemotherapy; HIPEC, hyperthermic intraperitoneal chemoperfusion.

Figure 1. Overall survival according to the pathological type (P=0.048). DPAM, disseminated peritoneal adenomucinosis; PMCA-I/D, peritoneal mucinous carcinomatosis with intermediate or discordant features; PMCA, peritoneal mucinous carcinomatosis.
levels of tumor markers (P=0.027; Fig. 3) to be a prognostic factor for survival time. Treatment did not improve patient prognosis, unlike pathological type.

The multivariate analysis identified pathological type as an independent prognostic influence on survival (P=0.033; Table III). The survival characteristics were significantly different between the DPAM and PMCA-I/D or PMCA groups. The prognosis was the most favorable for DPAM. No significant difference in survival was observed with regard to treatment method (PIC or HIPEC), gender, age and the baseline level of tumor markers. Multivariate analysis of recurrence-free survival identified two significant factors: the pathological subtype (P=0.042) and the use of HIPEC (P=0.017; Table IV).

Discussion

PMP is a low-grade malignant tumor. It is considered to be a secondary disease that originates from the appendix or ovaries (4,5). PMP generally exhibits no metastasis and rarely affects neighboring organs. The likely pathogenesis includes dissemination occurring by the rupture of appendicular adenocarcinoma or ovarian tumors with the release of neoplastic cells of mucous into the abdominal cavity. This is known as the redistribution phenomenon (6). The production of copious amounts of mucinous fluid results in a ‘jelly belly’, where the mucinous fluid accumulates in the abdomen.

PMP is a slowly progressive disease, and the pathological morphology is benign or of low-grade malignancy in the
majority of cases; however, its biological behavior is malignant, and it is not able to be removed completely during surgery. Relapse may occur easily. Postoperative recurrence occurs in 60-76% of patients and the patients may have to undergo secondary surgical resections. In this study, 25 cases of PMP recurred, of which 13 cases received the second debulking surgery. The median recurrence time was four months. The recurrence-free survival rates were 56 and 23% at one and three years, respectively.

It has previously been reported that the 5- and 10-year survival rates were 50.0-81.0 and 18.2-32.0%, respectively (7). In France, a large multicentric retrospective study of 301 patients reported that the 5-year overall and disease-free survival rates were 73 and 56%, respectively (8). Furthermore, a total of 103 patients were treated at The Netherlands Cancer Institute (Amsterdam, The Netherlands), and the 3- and 5-year disease-free survival probabilities were revealed to be 43.6 and 37.4%, respectively (9). In the present study, the median OS was 37 months. With a mean follow-up of 40 months, the overall 5- and 10-year survival rates were 89 and 35%, respectively. Taking the small number of cases for the analysis into account, the statistical results may have been influenced. The 5-year survival rate was higher than that reported in the aforementioned studies.

The elevated baseline levels of CEA, AFP and CA125 were useful for diagnosing this disease. Hsieh et al (10) suggested that preoperatively positive CEA and CA19.9 may normalize following surgery. An increasing level of CEA and CA19-9 prognosticates early recurrence. In a study by Carmignani et al (11), survival was associated with preoperative CEA and CA19.9 determination. Among 532 patients, the increasing CEA level was 58% and CA19.9 level was 67.1% higher than the baseline level within one week. The elevated levels of CEA and CA19.9 were not correlated with prognosis; however, poor prognosis was associated with an elevated CEA level prior to the second surgery. Short progression-free survival was associated with the preoperative baseline CA19.9 level and favorable prognosis was associated with a normal baseline level of CA125, as shown by Baratti et al (12). The present study revealed that preoperative elevated baseline levels of tumor markers prolonged the survival time in univariate analyses (P=0.027). Patients with normal baseline levels of tumor markers appeared to have a more favorable survival result. The reported prognostic factors of PMP are age (13), histology, residual tumor volume (14) and intraperitoneal chemotherapy (15). Ronnett et al (16) classified PMP into three histological subtypes: DPAM, PMCA and PMCA-I/D. According to the study by Ronnett et al, the 5-year survival postoperatively was 75% and the 10-year survival was 68% with DPAM; this was compared with 14 and 3%, respectively, with PMCA and 50 and 21%, respectively, with PMCA-I/D. The data indicated that histological type was a significant factor for treatment and prognosis. The multivariate analysis in the present study also demonstrated that histological type was able to act as an independent prognostic factor (P=0.033). Complete CRS was able to reduce the negative prognostic impact of the pathological grade, as previously demonstrated by Elias et al (17). It appeared that for patients with the DPAM type, treatment supplemented by complete CRS may prolong long-term survival.

At present, it is generally accepted that aggressive CRS and HIPEC is a novel option to treat PMP. Surgical cytoreduction as a traditional treatment had a high recurrence rate, as reported by Sugarbaker (18), with a 5-year survival rate of only 20%. Furthermore, in the majority of the patients with PMP, recurrence occurred within 18 months. Repeated surgery was also likely to have increased the severity of the disease (19). According to the synergistic effect of thermochemotherapy and the different tolerances of tumors and normal tissue to temperature, Spratt et al (20) designed a novel treatment technique known as HIPEC. HIPEC was performed with a closed abdomen cavity for 60 min, at a temperature of 42-43°C, using perfusate mixed with a cytotoxic drug (fluorouracil or cisplatin). The hyperthermia potentiated tumor cells on the peritoneal surface to absorb high doses of cytotoxic drugs and increased local tissue drug concentration. The aim was to eliminate microscopic and minimal residual disease remaining in the abdominal cavity following surgical resection (21). Sugarbaker (22) used the combination of CRS with PIC to treat PMP. In a cohort of 205 patients, who were classified into two groups, the 5-year survival rate was 86% for patients with HIPEC and 20% for the patients with CRS only (23). Deraco et al (24,25) reported a 96% survival rate at five years in 22 patients with PMP treated with HIPEC, and recurrence occurred in only one patient within a year. This demonstrated that applying HIPEC to treat PMP, in order to reduce the postoperative recurrence rate, improved quality of life and the survival rate. A large multicentric retrospective study by Elias et al (8) indicated that CRS combined with HIPEC should be considered as the gold standard treatment of PMP. The study underlined the prognostic impact of the extent of peritoneal seeding, particularly in patients treated by complete CRS. This prognostic impact appeared to be greater than that of the pathological grade. In our study, hyperthermic intraperitoneal chemotherapy did not have a more favorable OS rate than intraoperative intraperitoneal chemotherapy or no chemotherapy. In the present study, the recurrence time subsequent to surgery was reported from the data of the CRS and HIPEC treatment. It was suggested that this was a more accurate representation of the impact of treatment on the course of the disease. In a report from the Mayo Clinic on a subgroup analysis of 31 patients with incomplete surgical removal of mucus, intra-abdominal chemotheraphy significantly reduced the recurrence (26). In the present study, HIPEC with CRS was correlated with recurrence-free survival, as shown by multivariate analysis (Table IV). As long as PMP recurred, the treatment of surgical debulking was repeated, as necessary, to alleviate pressure (26). However, repeated surgeries became more difficult due to progressively thickened intra-abdominal adhesions (27); therefore, a longer recurrence time following initial surgery was necessary to mitigate symptoms and improve the quality of life.

There were few clinical data to support how to prolong postoperative recurrence time. In the present study, stepwise multivariate Cox proportional-hazard regression analysis indicated that pathological classification and HIPEC were independent predictors of recurrence-free survival. However, due to the small sample size and the retrospective nature of the study, larger multicenter studies are required in the future.

In conclusion, the pathological subtype remained the dominant factor for survival. The efficacy of CRS with HIPEC
was demonstrated in the treatment of PMP by prolonging the postoperative recurrence time. Patients with normal baseline levels of tumor markers appeared to have an improved survival result.

References

1. Wertheim I, Fleischhacker D, McLachlin CM, Rice LW, Berkowitz RS and Joffe BA: Pseudomyxoma Peritonei: a review of 23 cases. Obstet Gynecol 84: 17-21, 1994.
2. Guo AT, Song X, Wei LX and Zhao P: Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry. World J Gastroenterol 17: 3531-3537, 2011.
3. Sugarbaker PH: Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 27: 239-243, 2001.
4. Young RH, Gilks CB and Scully RE: Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. Am J Surg Pathol 15: 415-429, 1991.
5. Szych C, Staebler A, Connolly DC, et al: Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. Am J Pathol 154: 1849-1855, 1999.
6. Zhou Z, Mo CC, Zhuang JY and Deng ZH: Pseudomixoma peritonei associated with ovary and omentum majus: 1 case report. Journal of Guiyang Medical College 28: 186-192, 2003 (In Chinese).
7. Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF and Coit DG: Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 241: 300-308, 2005.
8. Elias D, Gilly F, Quenet F, Bereder JM, et al: Pseudomyxoma peritonei: A French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 36: 456-462, 2010.
9. Smeenk RM, Verwaal VJ, Antonini N and Zoetmulder FA: Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg 245: 104-109, 2007.
10. Hsieh SY, Chiu CT, Sheen IS, Lin DY and Wu CS: A clinical study on pseudomyxoma peritonei. J Gastroenterol Hepatol 10: 86-91, 1995.
11. Carmignani CP, Hampton R, Sugarbaker CE, Chang D and Sugarbaker PH: Utility of CEA and CA19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol 87: 162-166, 2004.
12. Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG and Deraco M: Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 14: 2300-2308, 2007.
13. Lee JK, Song SH, Kim I, Lee KH, Kim BG, Kim JW, Kim YT, Park SY, Cha MS and Kang SB: Retrospective multicenter study of a clinicopathologic analysis of pseudomixoma peritonei associated with ovarian tumors (KGOG 3005). Int J Gynecol Cancer 18: 916-920, 2008.
14. Miner TJ, Shia J, Jaques DP, et al: Long-term survival following treatment of pseudomixoma peritonei: an analysis of surgical therapy. Ann Surg 241: 300-308, 2005.
15. Baratti D, Kusamura S, Nonaka D, et al: Pseudomyxoma Peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 15: 526-534, 2008.
16. Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L and Sugarbaker PH: Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92: 85-91, 2001.
17. Elias D, Honoré C, Ciuchendéa R, et al: Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg 95: 1164-1171, 2008.
18. Sugarbaker PH: Pseudomyxoma peritonei: a cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 219: 109-111, 1994.
19. Wu B and Wu HP: Diagnosis and treatment of Pseudomyxoma peritonei: 5 cases report. Journal of Abdominal Surgery 10: 228-229, 1997 (In Chinese).
20. Spratt JS, Adcock RA, Sherrill W and Travathen S: Hyperthermic peritoneal perfusion system in canines. Cancer Res 40: 253-255, 1980.
21. Zhang SH and Liu ZL: Pseudomyxoma peritonei: the treatment experience of 9 cases. Chinese Journal of Clinical Oncology 26: 1-12, 1999 (In Chinese).
22. Sugarbaker PH: Pseudomyxoma peritonei: a cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 219: 109-111, 1994.
23. Sugarbaker PH: Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 27: 239-243, 2001.
24. Deraco M, Kusamura S and Gronchi A: Cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic chemotherapy: an innovative and effective approach to the treatment of pseudomyxoma peritonei. Tumor 89: 54-55, 2003 (In Italian).
25. Deraco M, Gronchi A, Mazzaferrro V, et al: Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with pseudomyxoma peritonei. Tumori 88: 570-575, 2002.
26. Gough DB, Donohue JH, Schutt AJ, et al: Pseudomyxoma peritonei: Long term patient survival with an aggressive regional approach. Ann Surg 219: 112-119, 1994.
27. Yan TD, Black D, Savady R and Sugarbaker PH: A systematic review of the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 14: 484-492, 2007.